Cargando…
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
INTRODUCTION: In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results of assessment of heterogeneity of treatment...
Autores principales: | Brown, Samuel M., Katz, Morgan J., Ginde, Adit A., Juneja, Kavita, Ramchandani, Monica, Schiffer, Joshua T., Vaca, Carlos, Gottlieb, Robert L., Tian, Yuan, Elboudwarej, Emon, Hill, Joshua A., Gilson, Richard, Rodriguez, Lauren, Hedskog, Charlotte, Chen, Shuguang, Montezuma-Rusca, Jairo M., Osinusi, Anu, Paredes, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113728/ https://www.ncbi.nlm.nih.gov/pubmed/37074613 http://dx.doi.org/10.1007/s40121-023-00789-y |
Ejemplares similares
-
LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hill, Joshua A, et al.
Publicado: (2021) -
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
por: Gottlieb, Robert L., et al.
Publicado: (2021) -
Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting
por: Pan, David Z., et al.
Publicado: (2023) -
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023) -
557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
por: Arribas, Jose Ramon, et al.
Publicado: (2020)